Summary
Background Association between DPP4 inhibitors and respiratory infection remains unclear. CardioVascular Outcomes Trials (CVOTs) conducted before the COVID-19 pandemic are available. We aimed to estimate the effect of DPP4 inhibitors on the risk of respiratory infections.
Methods We updated a previous systematic review and meta-analysis, searching for CVOTs assessing a DPP4 inhibitor in patients with type 2 diabetes mellitus. We focused on placebo-controlled CVOTs. Our primary outcome was ‘any respiratory infection’. We added a sensitivity analysis integrating non-CVOTs and active-controlled CVOTs.
Findings We included 47 714 patients in five placebo-controlled CVOTs. Median follow-up ranged from 1·5 years to 3 years. 4 369 events of overall respiratory infection were reported (rate of 9·2%). DPP4 inhibitors were not associated with a different risk compared to placebo (RR = 0·99 [95% CI: 0·93; 1·04]). The sensitivity analysis integrating the non-CVOTs studies and the active-controlled CVOT reached 11 349 events among 82 644 participants (rate of 13·7%). DPP4 inhibitors were not associated with a different risk of overall respiratory infection (RR = 1·00 [95% CI: 0·97; 1·03]).
Interpretation Our up-dated meta-analysis provides the most powerful and least biased estimation of the association of DPP4 inhibitors and the risk of overall (non COVID-19) respiratory infection. We did not find any effect of the DPP4 inhibitors on the risk of respiratory infection. Our results support the recently published practical recommendations for the management of diabetes in patients with COVID-19, suggesting that DPP4 inhibitors should not be discontinued regarding the COVID-19 pandemic.
Funding No source of funding
Evidence before this study From before the COVID19 pandemic, respiratory infections are considered potential adverse effects of DPP4 inhibitors. Randomized trials assessing DPP4 inhibitors in patients with type 2 diabetes (T2D), their meta-analyses and pharmacovigilance studies reported conflicting results. Since the last meta-analyses assessing the risk of infections with DPP4 inhibitors, powerful cardiovascular outcomes randomized trials (CVOTs) became available. Recent practical recommendations for the management of diabetes during COVID-19 suggested that DPP4 inhibitors could be continued. We updated our previous meta-analysis of CVOTs and focused to the overall risk of respiratory infection associated with DPP4 inhibitors. We searched for published and unpublished CVOTs in Medline, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov, up to January 27, 2020, using key word as “diabetes mellitus”, “hypoglycemic agents”, “glucose control”, “randomized controlled trial”, “cardiovascular diseases”.
Added value of this study We included CVOTs comparing a DPP4 inhibitor versus placebo, in people with T2D, and analysed the risk of respiratory infection with DPP4 inhibitors. We focused on placebo-controlled CVOTs to avoid the pitfalls of small study effect and heterogeneous comparators. We added a sensitivity analysis integrating non-CVOTs and non-placebo CVOTs to challenge our results and to increase the statistical power. Our meta-analysis provides the most powerful and least biased estimation of the association of DPP4 inhibitors and the risk of overall (non COVID-19) respiratory infection. Our analyses integrated 11 349 events of any respiratory infections through 82 644 patients from randomized trials. Our results did not find any association between DPP4 inhibitors use and risk of non-COVID respiratory infections.
Implications of all the available evidence The current COVID-19 pandemic has raised some questions about pros and cons of certain cardiovascular drugs. Our results support the recent practical recommendations for the management of diabetes in patients with COVID-19, suggesting that DPP4 inhibitors should not be discontinued regarding the COVID-19 pandemic.
Competing Interest Statement
GG, SMe, SMa, MA, CC, JLC, declare that they have no competing interest. JLC reports investigator driven grants from Bioprojet Pharma, Pfizer and United Therapeutics outside the submitted work. JCL has received speaking fees and honoraria from Roche. MC has received consulting fees from Boehringer Ingelheim, SANOFI, AstraZeneca and speaker honoraria from SANOFI. In the last five years, FG received for his institution fees from Portola Pharmaceuticals for central reading of ultrasound records, from Neurochlore for DSMB coordination, from EryTech Pharma for modeling projects, from RCTs and Steve Consultant for exploring French social security database.
Funding Statement
No source of funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval and consent to participate: not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available in the forest plots of the appendix.
Abbreviations
- AE
- Adverse Events
- 95% CI
- 95% Confidence Intervals
- ALRTI
- Any Lower Respiratory Tract Infection
- APT
- Antiplatelet Treatment
- ARI
- Any Respiratory Infection
- AURTI
- Any Upper Respiratory Tract Infection
- BMI
- Body Mass Index
- CENTRAL
- Cochrane Central Register of Controlled Trials
- CVOT
- CardioVascular Outcomes Trials
- DPP-4
- DiPeptidyl Peptidase-4
- GLP1
- Glucagon-Like Peptide-1
- HbA1c
- Glycated Hemoglobin
- HBP
- High Blood Pressure or antihypertensive drugs treatment
- Lipd
- Dyslipidemia or statins treatment
- LRTI
- Lower Respiratory Tract Infection
- MedDRA
- Medical Dictionary for Regulatory Activities
- NR
- Not Reported
- PRISMA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- RCT
- Randomized Clinical Trials
- RR
- Risk Ratio
- RTI
- Respiratory Tract Infection
- S.A
- Sensitivity Analysis
- SAE
- Serious Adverse Events
- SD
- Standard Deviation
- SGLT2
- Sodium-Glucose Cotransporter-2
- Smoker
- Current smoker
- T2D
- Type 2 Diabetes
- URTI
- Upper Respiratory Tract Infection
